<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790335</url>
  </required_header>
  <id_info>
    <org_study_id>22326953211</org_study_id>
    <secondary_id>U01HL088476-01A1</secondary_id>
    <nct_id>NCT00790335</nct_id>
  </id_info>
  <brief_title>Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis</brief_title>
  <acronym>ATTRACT</acronym>
  <official_title>Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>BSN Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mid America Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Interventional Radiology Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of adjunctive Pharmacomechanical
      Catheter Directed Thrombolysis, which includes the intrathrombus administration of
      rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with
      symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Activase, the study drug, is a fibrinolytic drug that is indicated for use in acute
      myocardial infarction, acute ischemic stroke, and acute massive pulmonary embolism in adults.
      Previous studies have established the ability of rt-PA to lyse venous thrombus in patients
      with deep vein thrombosis (DVT), and suggest that successful rt-PA mediated thrombolysis can
      prevent the post-thrombotic syndrome (PTS), a morbid, late complication of DVT that occurs in
      nearly 50% of patients.

      rt-PA is delivered directly into venous thrombus using a catheter/device which is embedded
      within the thrombus by a physician under imaging guidance. This method of rt-PA delivery,
      pharmacomechanical catheter-directed intrathrombus thrombolysis (PCDT),is thought to be
      safer, more effective, and more efficient than previous methods. The question of whether PCDT
      using rt-PA improves long-term DVT patient outcomes with acceptable risk and cost has not yet
      been addressed.

      The rationale for performing the ATTRACT Trial is based upon:

        -  the major burden of PTS on DVT patients and the U.S. healthcare system

        -  the association between rapid clot lysis and prevention of PTS

        -  the proven ability of rt-PA to dissolve venous thrombus in proximal DVT

        -  recent advances in CDT methods which may lower bleeding risk

        -  the major clinical controversy on whether CDT should be routinely used for first-line
           DVT therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale)</measure>
    <time_frame>Between 6 and 24 months after randomization</time_frame>
    <description>Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Non-post-thrombotic Syndrome Treatment Failure</measure>
    <time_frame>Through 24 months</time_frame>
    <description>A major non-post-thrombotic-syndrome treatment failure refers to when any of three events occurred in the index leg: 1) an unplanned endovascular procedure to treat severe venous symptoms within 6 months post-randomization; 2) venous gangrene within 6 months; or 3) an amputation within 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Treatment Failure</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Composite of PTS and major non-PTS treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate-to-severe Post-thrombotic Syndrome</measure>
    <time_frame>Between 6 and 24 months after randomization</time_frame>
    <description>Proportion of patients with Villalta score of 10 or higher at any time between the 6 month and 24 month follow-up visits, inclusive. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Within 10 days after randomization</time_frame>
    <description>Defined as clinically overt bleeding that is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Within 24 months after randomization</time_frame>
    <description>Defined as clinically overt bleeding that was associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any (Minor + Major) Bleeding</measure>
    <time_frame>Within 10 days after randomization</time_frame>
    <description>Clinically overt bleeding that occurred through 10 days post-randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any (Major + Minor) Bleeding</measure>
    <time_frame>Within 24 months after randomization</time_frame>
    <description>Clinically overt bleeding that occurred within 24 months post-randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Venous Thromboembolism</measure>
    <time_frame>Within 10 days after randomization</time_frame>
    <description>Proportion of patients with symptomatic recurrent venous thromboembolism (including DVT and/or PE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Venous Thromboembolism</measure>
    <time_frame>Within 24 months after randomization</time_frame>
    <description>Symptomatic recurrent venous thromboembolism (DVT and/or PE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Within 10 days after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Within 24 months after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-thrombotic Syndrome (Villalta)</measure>
    <time_frame>At 6 months</time_frame>
    <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-thrombotic Syndrome (Villalta)</measure>
    <time_frame>At 12 months</time_frame>
    <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-thrombotic Syndrome (Villalta)</measure>
    <time_frame>At 18 months</time_frame>
    <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-thrombotic Syndrome (Villalta)</measure>
    <time_frame>At 24 months</time_frame>
    <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity Score</measure>
    <time_frame>At 6 months</time_frame>
    <description>Mean Venous Clinical Severity Score (VCSS) at the specified follow-up visit; range 0-27 (did not use compression item), higher score is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity Score</measure>
    <time_frame>At 12 months</time_frame>
    <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity Score</measure>
    <time_frame>At 18 months</time_frame>
    <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity Score</measure>
    <time_frame>At 24 months</time_frame>
    <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in General Quality of Life - Physical</measure>
    <time_frame>Baseline to 24 months post-randomization</time_frame>
    <description>Short-Form-36 Health Survey, Version 2, Physical Component Summary (PCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in General Quality of Life - Mental</measure>
    <time_frame>Baseline to 24 months post-randomization</time_frame>
    <description>Short-Form-36 Health Survey, Version 2, Mental Component Summary (MCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Disease-specific Quality of Life</measure>
    <time_frame>Baseline to 24 months post-randomization</time_frame>
    <description>Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) questionnaire. Range of scores 0-100 with higher scores representing better quality of life, and higher change scores representing greater improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Pain Severity</measure>
    <time_frame>Baseline to 10 days post-randomization</time_frame>
    <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Pain Severity</measure>
    <time_frame>Baseline to 30 days post-randomization</time_frame>
    <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Circumference</measure>
    <time_frame>Baseline to 10 days post-randomization</time_frame>
    <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leg Circumference</measure>
    <time_frame>Baseline to 30 days post-randomization</time_frame>
    <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">692</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Postphlebitic Syndrome</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>A-Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant tissue plasminogen activator (rt-PA)</intervention_name>
    <description>Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
    <arm_group_label>A-Intervention</arm_group_label>
    <other_name>rt-PA</other_name>
    <other_name>recombinant tissue plasminogen activator</other_name>
    <other_name>Activase</other_name>
    <other_name>Alteplase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic proximal DVT involving the iliac, common femoral, and/or femoral vein.

        Exclusion Criteria:

          -  Age less than 16 years or greater than 75 years.

          -  Symptom duration &gt; 14 days for the DVT episode in the index leg (i.e., non-acute DVT).

          -  In the index leg: established PTS, or previous symptomatic DVT within the last 2
             years.

          -  In the contralateral (non-index) leg: symptomatic acute DVT a) involving the iliac
             and/or common femoral vein; or b) for which thrombolysis is planned as part of the
             initial therapy.

          -  Limb-threatening circulatory compromise.

          -  Pulmonary embolism with hemodynamic compromise (i.e., hypotension).

          -  Inability to tolerate PCDT procedure due to severe dyspnea or acute systemic illness.

          -  Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated
             contrast, except for mild-moderate contrast allergies for which steroid pre-medication
             can be used.

          -  Hemoglobin &lt; 9.0 mg/dl, INR &gt; 1.6 before warfarin was started, or platelets &lt;
             100,000/ml.

          -  Moderate renal impairment in diabetic patients (estimated glomerular filtration rate
             [GFR] &lt; 60 ml/min) or severe renal impairment in non-diabetic patients (estimated GFR
             &lt; 30 ml/min).

          -  Active bleeding, recent (&lt; 3 mo) GI bleeding, severe liver dysfunction, bleeding
             diathesis.

          -  Recent (&lt; 3 mo) internal eye surgery or hemorrhagic retinopathy; recent (&lt; 10 days)
             major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical
             delivery, or other invasive procedure.

          -  History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation,
             aneurysm.

          -  Active cancer (metastatic, progressive, or treated within the last 6 months).
             Exception: patients with non-melanoma primary skin cancers are eligible to participate
             in the study.

          -  Severe hypertension on repeated readings (systolic &gt; 180 mmHg or diastolic &gt; 105
             mmHg).

          -  Pregnant (positive pregnancy test, women of childbearing potential must be tested).

          -  Recently (&lt; 1 mo) had thrombolysis or is participating in another investigational drug
             study.

          -  Use of a thienopyridine antiplatelet drug (except clopidogrel) in the last 5 days.

          -  Life expectancy &lt; 2 years or chronic non-ambulatory status.

          -  Inability to provide informed consent or to comply with study assessments (e.g. due to
             cognitive impairment or geographic distance).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Vedantham, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Coordinating Center at Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clive Kearon, MB, MRCP, FRCP(C), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Data Coordinating Center at McMaster University-Ontario Clinical Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Z Goldhaber, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arrowhead Hospital/Phoenix Heart, PLLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Systems</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mease Countryside Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac &amp; Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital-Tampa Division-Pepin Heart Institute and Dr. Kiran C. Patel Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adventist Midwest Health</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CorVasc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Carver's College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare of Northern Kentucky</name>
      <address>
        <city>Florence</city>
        <state>Kentucky</state>
        <zip>41042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann Arbor Veteran's Administration Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Elizabeth Regional Medical Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510-2494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Hospital</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Weill Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jobst Vascular Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Presbyterian Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, Ltd.</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin/Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.annals.org/cgi/content/abstract/125/1/1</url>
    <description>The Long-Term Clinical Course of Acute Deep Vein Thrombosis</description>
  </link>
  <link>
    <url>http://www3.interscience.wiley.com/journal/118716923/abstract?CRETRY=1&amp;SRETRY=O</url>
    <description>Predictors of the Post Thrombotic Syndrome During Long-Term Treatment of Proximal Deep Vein Thrombosis</description>
  </link>
  <link>
    <url>http://www.patient.co.uk/showdoc/23068982</url>
    <description>Deep Vein Thrombosis</description>
  </link>
  <link>
    <url>http://www.annals.org/cgi/content/abstract/141/4/249</url>
    <description>Below-Knee Elastic Compression Stockings to Prevent the Post Thrombotic Syndrome</description>
  </link>
  <reference>
    <citation>Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658. Erratum in: Chest. 2008 Oct;134(4):892.</citation>
    <PMID>18574272</PMID>
  </reference>
  <reference>
    <citation>Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis. 2006 Feb;21(1):41-8. Review.</citation>
    <PMID>16475040</PMID>
  </reference>
  <reference>
    <citation>Vedantham S, Millward SF, Cardella JF, Hofmann LV, Razavi MK, Grassi CJ, Sacks D, Kinney TB; Society of Interventional Radiology. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Radiol. 2006 Apr;17(4):613-6.</citation>
    <PMID>16614142</PMID>
  </reference>
  <reference>
    <citation>Vedantham S, Vesely TM, Sicard GA, Brown D, Rubin B, Sanchez LA, Parti N, Picus D. Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol. 2004 Jun;15(6):565-74.</citation>
    <PMID>15178716</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>December 18, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>deep venous thrombosis</keyword>
  <keyword>post thrombotic syndrome</keyword>
  <keyword>blood clot</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>tissue plasminogen activator</keyword>
  <keyword>rt-PA</keyword>
  <keyword>Activase</keyword>
  <keyword>mechanical thrombectomy</keyword>
  <keyword>pharmacomechanical</keyword>
  <keyword>ATTRACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A-Intervention</title>
          <description>Pharmacomechanical catheter-directed thrombolysis (PCDT) with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
        </group>
        <group group_id="P2">
          <title>B-Control</title>
          <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio [INR} 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="355"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient was found not to meet the study inclusion criterion, and was excluded from all analyses by the adjudication committee.</population>
      <group_list>
        <group group_id="B1">
          <title>A-Intervention</title>
          <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
        </group>
        <group group_id="B2">
          <title>B-Control</title>
          <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="336"/>
            <count group_id="B2" value="355"/>
            <count group_id="B3" value="691"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="41" upper_limit="62"/>
                    <measurement group_id="B2" value="53" lower_limit="43" upper_limit="62"/>
                    <measurement group_id="B3" value="53" lower_limit="42" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="629"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <units>kilograms per square meter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="27" upper_limit="36"/>
                    <measurement group_id="B2" value="30" lower_limit="26" upper_limit="35"/>
                    <measurement group_id="B3" value="31" lower_limit="27" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom severity score</title>
          <description>The Villalta scale was used to define baseline symptom severity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None or very mild (0-4)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (5-9)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (10-14)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (&gt; 14)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not documented</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Side of index DVT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Left leg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right leg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous DVT or PE</title>
          <description>DVT = deep vein thrombosis; PE = pulmonary embolism</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous ipsilateral DVT</title>
          <description>DVT = deep vein thrombosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DVT extends into iliac or common femoral vein</title>
          <description>Patients with DVT extending into the iliac or common femoral vein are termed &quot;iliofemoral DVT&quot; and those whose DVT did not extend that high are termed &quot;femoropopliteal DVT&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DVT risk factors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Major surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hospitalization</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Plaster cast immobilization</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Childbirth</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None of the above risk factors</title>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Outpatient</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from symptom start to randomization</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="B2" value="6" lower_limit="4" upper_limit="9"/>
                    <measurement group_id="B3" value="6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspirin use within past 7 days</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate</title>
          <units>milliliters per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" lower_limit="70" upper_limit="102"/>
                    <measurement group_id="B2" value="86" lower_limit="71" upper_limit="102"/>
                    <measurement group_id="B3" value="86" lower_limit="71" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High cholesterol</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disease</title>
          <description>COPD = chronic obstructive pulmonary disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina or myocardial infarction</title>
          <description>MI = myocardial infarction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174" spread="11"/>
                    <measurement group_id="B2" value="174" spread="10"/>
                    <measurement group_id="B3" value="174" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97" spread="25"/>
                    <measurement group_id="B2" value="96" spread="24"/>
                    <measurement group_id="B3" value="97" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale)</title>
        <description>Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>Between 6 and 24 months after randomization</time_frame>
        <population>Modified full analysis set; intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale)</title>
          <description>Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set; intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for extent of DVT and for clinical center</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm. Primary outcome = no statistically significant difference between the two arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Non-post-thrombotic Syndrome Treatment Failure</title>
        <description>A major non-post-thrombotic-syndrome treatment failure refers to when any of three events occurred in the index leg: 1) an unplanned endovascular procedure to treat severe venous symptoms within 6 months post-randomization; 2) venous gangrene within 6 months; or 3) an amputation within 24 months.</description>
        <time_frame>Through 24 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Major Non-post-thrombotic Syndrome Treatment Failure</title>
          <description>A major non-post-thrombotic-syndrome treatment failure refers to when any of three events occurred in the index leg: 1) an unplanned endovascular procedure to treat severe venous symptoms within 6 months post-randomization; 2) venous gangrene within 6 months; or 3) an amputation within 24 months.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm. No statistically significant difference was seen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Treatment Failure</title>
        <description>Composite of PTS and major non-PTS treatment failure</description>
        <time_frame>Through 24 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Any Treatment Failure</title>
          <description>Composite of PTS and major non-PTS treatment failure</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted for thrombus extent and clinical center</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>No statistically significant difference was seen.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moderate-to-severe Post-thrombotic Syndrome</title>
        <description>Proportion of patients with Villalta score of 10 or higher at any time between the 6 month and 24 month follow-up visits, inclusive. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>Between 6 and 24 months after randomization</time_frame>
        <population>Modified full analysis set, intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Moderate-to-severe Post-thrombotic Syndrome</title>
          <description>Proportion of patients with Villalta score of 10 or higher at any time between the 6 month and 24 month follow-up visits, inclusive. The Villalta scale ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set, intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusted by extent of DVT and clinical center</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding</title>
        <description>Defined as clinically overt bleeding that is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
        <time_frame>Within 10 days after randomization</time_frame>
        <population>Modified full analysis set, intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>Defined as clinically overt bleeding that is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
          <population>Modified full analysis set, intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>6.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>49.2</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm. More major bleeding was observed in the PCDT Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding</title>
        <description>Defined as clinically overt bleeding that was associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
        <time_frame>Within 24 months after randomization</time_frame>
        <population>Modified full analysis set; intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>Defined as clinically overt bleeding that was associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g. intracranial, intraspinal).</description>
          <population>Modified full analysis set; intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any (Minor + Major) Bleeding</title>
        <description>Clinically overt bleeding that occurred through 10 days post-randomization</description>
        <time_frame>Within 10 days after randomization</time_frame>
        <population>Modified full analysis set, intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Any (Minor + Major) Bleeding</title>
          <description>Clinically overt bleeding that occurred through 10 days post-randomization</description>
          <population>Modified full analysis set, intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
            <estimate_desc>Numerator = PCDT Arm; Denominator = Control Arm. Bleeding was more frequent in the PCDT Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any (Major + Minor) Bleeding</title>
        <description>Clinically overt bleeding that occurred within 24 months post-randomization</description>
        <time_frame>Within 24 months after randomization</time_frame>
        <population>Modified full analysis set, intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Any (Major + Minor) Bleeding</title>
          <description>Clinically overt bleeding that occurred within 24 months post-randomization</description>
          <population>Modified full analysis set, intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Venous Thromboembolism</title>
        <description>Proportion of patients with symptomatic recurrent venous thromboembolism (including DVT and/or PE)</description>
        <time_frame>Within 10 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Venous Thromboembolism</title>
          <description>Proportion of patients with symptomatic recurrent venous thromboembolism (including DVT and/or PE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>5.28</ci_upper_limit>
            <estimate_desc>Numerator = PCDT Arm; Denominator = Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Venous Thromboembolism</title>
        <description>Symptomatic recurrent venous thromboembolism (DVT and/or PE)</description>
        <time_frame>Within 24 months after randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Venous Thromboembolism</title>
          <description>Symptomatic recurrent venous thromboembolism (DVT and/or PE)</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
            <estimate_desc>Numerator: PCDT Arm; Denominator: Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>All-cause mortality</description>
        <time_frame>Within 10 days after randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>All-cause mortality</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>All-cause mortality</description>
        <time_frame>Within 24 months after randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>All-cause mortality</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
        <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>At 6 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
          <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="0.24"/>
                    <measurement group_id="O2" value="4.33" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
        <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>At 12 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
          <description>Mean Villalta scale score at the specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.22"/>
                    <measurement group_id="O2" value="4.38" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
        <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>At 18 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
          <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="0.24"/>
                    <measurement group_id="O2" value="4.44" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
        <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
        <time_frame>At 24 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Post-thrombotic Syndrome (Villalta)</title>
          <description>Mean Villalta scale score at specified follow-up visit. Villalta score ranges from 0-33 points, with higher scores being worse.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="0.28"/>
                    <measurement group_id="O2" value="4.50" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Clinical Severity Score</title>
        <description>Mean Venous Clinical Severity Score (VCSS) at the specified follow-up visit; range 0-27 (did not use compression item), higher score is worse</description>
        <time_frame>At 6 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Clinical Severity Score</title>
          <description>Mean Venous Clinical Severity Score (VCSS) at the specified follow-up visit; range 0-27 (did not use compression item), higher score is worse</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.15"/>
                    <measurement group_id="O2" value="2.68" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Clinical Severity Score</title>
        <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
        <time_frame>At 12 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Clinical Severity Score</title>
          <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.16"/>
                    <measurement group_id="O2" value="2.37" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Clinical Severity Score</title>
        <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
        <time_frame>At 18 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Clinical Severity Score</title>
          <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.17"/>
                    <measurement group_id="O2" value="2.80" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Clinical Severity Score</title>
        <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
        <time_frame>At 24 months</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Clinical Severity Score</title>
          <description>Mean VCSS score at the specified follow-up visit; range 0-27 (did not use compression item)</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.18"/>
                    <measurement group_id="O2" value="2.42" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Linear</method>
            <method_desc>Piecewise linear-regression growth-curve models with adjustment for extent of DVT, clinical center) and pre-specified baseline co-variates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Lower (better) mean scores in the PCDT Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in General Quality of Life - Physical</title>
        <description>Short-Form-36 Health Survey, Version 2, Physical Component Summary (PCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
        <time_frame>Baseline to 24 months post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in General Quality of Life - Physical</title>
          <description>Short-Form-36 Health Survey, Version 2, Physical Component Summary (PCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" spread="0.91"/>
                    <measurement group_id="O2" value="10.06" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.26</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>No significant difference was seen in the degree of change from baseline to 24 months between the two treatment arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in General Quality of Life - Mental</title>
        <description>Short-Form-36 Health Survey, Version 2, Mental Component Summary (MCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
        <time_frame>Baseline to 24 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in General Quality of Life - Mental</title>
          <description>Short-Form-36 Health Survey, Version 2, Mental Component Summary (MCS) Scale. Range of scores 0-100 with higher scores representing better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.84"/>
                    <measurement group_id="O2" value="2.70" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>No difference was observed in the degree of change from baseline to 24 months in the two treatment groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Disease-specific Quality of Life</title>
        <description>Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) questionnaire. Range of scores 0-100 with higher scores representing better quality of life, and higher change scores representing greater improvement from baseline.</description>
        <time_frame>Baseline to 24 months post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Venous Disease-specific Quality of Life</title>
          <description>Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL) questionnaire. Range of scores 0-100 with higher scores representing better quality of life, and higher change scores representing greater improvement from baseline.</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.67" spread="1.71"/>
                    <measurement group_id="O2" value="23.47" spread="17.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>No significant difference in the change from baseline to 24 months between the two treatment arms.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Pain Severity</title>
        <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
        <time_frame>Baseline to 10 days post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Pain Severity</title>
          <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="0.10"/>
                    <measurement group_id="O2" value="-1.29" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Pain Severity</title>
        <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
        <time_frame>Baseline to 30 days post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Pain Severity</title>
          <description>Likert pain scale ranging from 1-7, with higher scores representing a greater intensity of pain</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="0.11"/>
                    <measurement group_id="O2" value="-1.83" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Circumference</title>
        <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
        <time_frame>Baseline to 10 days post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Circumference</title>
          <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.17"/>
                    <measurement group_id="O2" value="0.27" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leg Circumference</title>
        <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
        <time_frame>Baseline to 30 days post-randomization</time_frame>
        <population>Modified full analysis set; intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>A-Intervention</title>
            <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
          </group>
          <group group_id="O2">
            <title>B-Control</title>
            <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leg Circumference</title>
          <description>Mean calf circumference measured 10 cm below the tibial tuberosity</description>
          <population>Modified full analysis set; intention to treat</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.17"/>
                    <measurement group_id="O2" value="-0.28" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Linear</method>
            <method_desc>Adjusted by extent of thrombus and clinical center</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected throughout the study - i.e. through 24 months post-randomization. Non-serious adverse events were collected through 30 days post-randomization, and through 30 days after any subsequent PCDT procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A-Intervention</title>
          <description>PCDT with intrathrombus delivery of rt-PA (maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
Recombinant tissue plasminogen activator (rt-PA): Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.</description>
        </group>
        <group group_id="E2">
          <title>B-Control</title>
          <description>Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target INR 2.0 - 3.0). Elastic compression stockings will be prescribed</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heparin induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mediastinal adenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute CHF with atrial fibrillation and rapid ventricular response</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute rejection (heart transplant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Aortic insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Asystole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atrial flutter with rapid ventricular response</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atypical chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Chest pain and shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Chest pain, shortness of breath, hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Coronary artery disease and hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency with CHF exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leg swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Non-ST wave myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute gallstone pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute on chronic pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute short bowel obstruction versus Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Antral gastritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bleeding gums</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Death secondary to metastatic gastric carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diverticulosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Esophageal stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea, vomiting, diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Obstipation with ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="336"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Multisystem organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary diskinesia and sludge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Angioedema, unclear etiology</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab results secondary to undetermined infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute viral gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bilateral lower extremity cellulitis and CHF</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gangrene left hallux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Influenza A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Intra-abdominal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Post-operative infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Right hand abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sepsis and pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Staph infection in right shoulder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Suspected infection to stump from right below-knee amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Viral gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Viral syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomoting and diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acute oxycodone and doxylamine intoxication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute phencyclidine intoxication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Alcohol intoxication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Broken ribs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Disconnected VP shunt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fall after alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fracture and cellulitis of right first toe</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fractured humerus and ribs - fell off ladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gunshot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection secondary to bile leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Migrated VP shunt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Methicillin-resistant Staphylococcus Aureus - wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Post-percardiotomy syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Right knee tear of medial meniscus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Spinal headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ventricular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated INR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated troponin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Low hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mania, bizarre behavior, agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lactic acidosis, acute sepsis, atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Back spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Complex gouty septic olecranon bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Foot pain/burning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Herniated lumbar disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Left C4-C5 neuroforaminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Left lower extremity pain and abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leg pain and swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Severe bilateral knee degenerative joint disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of unknown primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Breast intraductal papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Colon cancer - adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastric adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Kidney cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Metastatic adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pancreatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of unknown primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Surgical excision of squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and progressive cauda equina syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Blurred vision and diffuse itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>C5 on C6 retrolisthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Massive closed head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Reversible cerebral vasoconstriction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Transient dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Transient ischemia attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Withdrawal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Altered mental state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Short-term memory impairment of uncertain etiology</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Suicidal ideation and alcohol withdrawal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="336"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Obstructing ureteral stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Renal vein obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary tract infection and cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Uterine bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute on chronic respiratory insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Chest pain/asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dyspnea with lower extremity edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoxia due to hypoventilation due to multiple pain medications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Metastatic lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pleuritic chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pneumonia and pulmonary hypertension likely due to PE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="336"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intertigo labialis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Debridement of right below-the-knee amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Degenerative joint disease with total right hip replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Left hip removal of hardware and total hip arthoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Right foot amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute arterial limb ischemia of left lower extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acute right lower extremity DVT and acute bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Arterial occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bleeding at sheath puncture site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bleeding from wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>DVT and PE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemoperitoneum of unknown etiology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhagic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypovolemic shocck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Orthostatic hyptension secondary to beta blockers and dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Peripheral arterial disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="336"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Right knee hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Syncope and head contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Type A ascending aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Venous thromboembolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Retroperitoneal bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Suresh Vedantham, Principal Investigator</name_or_title>
      <organization>Washington University in St. Louis</organization>
      <phone>3143622900 ext 314</phone>
      <email>vedanthams@mir.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

